Search

WuXiBody is a bispecific antibody (bsAb) platform developed by WuXi Biologics. Its key feature is the replacement of one parental antibody's CH1/CL region with the T cell receptor (TCR) constant domain, a design that promotes cognate heavy chain (HC)-light chain (LC) pairing. BsAbs based on WuXiBody can adopt either asymmetric or symmetric format. For purifying a WuXiBody-based symmetric bsAb, we identified a LC-missing species as a major byproduct. While for bsAbs based on other platforms removal of such byproduct can pose considerable challenge to the downstream team, in this case WuXiBody's unique design makes separation relatively straightforward. We previously showed that Capto MMC ImpRes mixed-mode chromatography under bind-elute mode can effectively remove this LC-missing species. However, the dynamic binding capacity (DBC) of Capto MMC ImpRes is relatively low under the selected condition, making the process less desirable for large-scale manufacturing. In this study, we demonstrated that when Capto MMC ImpRes chromatography is conducted under weak partitioning mode, high throughput, good yield, and effective byproduct removal are simultaneously achieved. • A key feature of WuXiBody bsAb platform is the replacement of one parental mAb's CH1/CL region with the TCR constant domain. • LC-missing species are potential byproducts associated with bsAbs containing engineered Fab arm, including WuXi Bodies. • While the LC-missing byproduct can be removed by MMC ImpRes under bind-elute mode, the binding capacity is relatively low. • Upon switching to weak partitioning mode, high throughput, good yield and byproduct clearance are simultaneously achieved. [ABSTRACT FROM AUTHOR]